Physician profile
Subhash C Sharma
NPI 1528111903
$946.72
in general payments reported to CMS, 2019-2025
25 companies · $60.29 in 2025
The $60.29 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $71.24 · 2022: $70.39 · 2023: $268 · 2024: $174 · 2025: $60.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.38 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $131.41 | 2019-2023 | Opdivo |
| Inari Medical, INC. | $98.32 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $97.19 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $69.89 | 2019-2025 | Enhertu |
| Lilly USA, LLC | $68.09 | 2019-2023 | Jaypirca, Retevmo |
| Celgene Corporation | $60.76 | 2022-2024 | Reblozyl |
| Merck Sharp & Dohme LLC | $56.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $45.14 | 2023 | |
| Rigel Pharmaceuticals, INC. | $39.38 | 2023 | Rezlidhia, Tavalisse |
| Astellas Pharma US INC | $37.85 | 2019 | |
| Daiichi Sankyo INC. | $37.33 | 2023 | Injectafer |
| Pharmaessentia USA Corporation | $37.26 | 2023 | Besremi |
| Puma Biotechnology, INC. | $32.53 | 2019-2020 | |
| Genzyme Corporation | $20.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.21 | 2024 | Libtayo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $17.04 | 2025 | Sancuso |
| Gilead Sciences, INC. | $16.01 | 2023 | |
| Aurobindo Pharma USA, INC. | $15.13 | 2019 | |
| Eisai INC. | $13.22 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $13.08 | 2023 | Somatuline Depot, Onivyde |
| Teva Pharmaceuticals USA, INC. | $11.77 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $11.76 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhash Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.